Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Almirall SA    ALM   ES0157097017

ALMIRALL SA (ALM)
Mes dernières consult.
Most popular
End-of-day quote. End-of-day quote  - 11/21
8.34 EUR   +0.85%
11/06 ALMIRALL : Q3 results 2017
11/01ALMIRALL SA : quaterly earnings release
10/27 ALMIRALL : New randomized controlled study confirms the efficacy and..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Almirall : collaborates with ICMAB-CSIC and Leitat Technology Center in Nanomedicine applied to Dermatology

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/18/2017 | 04:08pm CET

Almirall, S.A. announced today the launch of Nano4Derm, a research project in collaboration with the Institute of Material Science of Barcelona from CSIC (ICMAB-CSIC), and Leitat Technology Center, focused in nanomedicine applied to treat dermatological diseases. Within the framework of this research project, new innovative formulations containing nanoencapsulated active ingredients will be developed for the topical treatment of inflammatory skin conditions, such as Acne and Psoriasis.

Nano4Derm involves the development and physico-chemical and biological characterisation of nanocapsules containing active ingredients, and the generation of scalable formulation prototypes for manufacturing nanoformulations suitable for clinical trials. These innovative formulations will address current unmet needs and challenges, such as antimicrobial resistance, and provide improved topical treatments for Acne and Psoriasis, in terms of side effects, instability of active ingredients, and skin penetration.

Under the terms of the agreement, ICMAB-CSIC and Leitat research centers will be in charge of developing the different prototypes of nanocapsules containing the active ingredients while Almirall will be responsible for the development of formulations containing the encapsulated actives. Furthermore, Almirall and Leitat will evaluate in preclinical studies both the new nanocapsules and formulations in order to select the best solution to address the unmet medical needs in the topical treatment of Acne and Psoriasis.

This agreement will lead to the development of two types of nanocapsules: Quatsomes and Polymeric Nanocapsules. Quatsomes are lipid nanoparticles with higher colloidal stability than liposomes, which favors the production of high quality, pharmaceutical formulations. They are obtained from the DELOS-SUSP, a technology developed by researchers from the Nanomol group (ICMAB-CSIC) based on the use of supercritical fluids such as CO. This technology has advantages over other manufacturing methodologies in terms of homogeneity and scalability, as it replaces the use of organic solvents by green solvents. Polymeric Nanocapsules are developed by the Leitat Technology Center, and provide versatility to the project as they can be designed with different drug release profiles depending on the needs being addressed.

This project is funded by the Spanish Ministry of Economy, Industry and Competitiveness (MINECO) through the announcement of the State Program for R&D&i (2016), orientated to the Society Challenges, modality RETOS-Collaboration 2016, and co-financed by FEDER funds from the European Commission.

About Nanomol (ICMAB-CSIC)

NANOMOL is a research group depending on the Institute of Material Science of Barcelona from CSIC, with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties. NANOMOL is also a member of Biomedical Research Networking center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and of the technology transfer network TECNIO from ACC1Ó-Generalitat de Catalunya. The development by Nanomol of the different prototypes of nanocapsules will be performed in the ICTS 'NANBIOSIS', more specifically by the Biomaterial Processing and Nanostructuring Unit (U6) of the CIBER in Bioengineering, Biomaterials & NanomedicIne located at the ICMAB-CSIC.

About Leitat

Leitat is a multisectoral private technological center whose mission is to collaborate with companies and other entities to create economic, social and sustainable value, through R+D+2i projects and technological processes from innovation and creativity. Leitat is a brand of the private entity Acondicionamiento Tarrasense and is recognized by the Generalitat de Catalunya (ACCIÓ) and by MINECO.

The Division of Nanomedicine and nanobiosensors of Leitat develops nanosystems for therapeutic application in order to solve specific problems in safety and, absorption issues and improvement of the efficacy of some API. In addition, related to diagnosis the group develops nanoparticles for specific recognition of analytes for the improvement of the sensitivity and signal amplification of biosensor systems.

The Efficacy and Safety Unit of Leitat also participates in Nano4Derm project, which has extensive experience in the development and application of in vitro models for the toxicological and efficacy evaluation of diverse natural products, from the pharmaceutical, chemical, cosmetics and food industries. In the pharmaceutical sector, the Unit acts as a strategic provider in Drug Discovery and pharmaceutical development processes. In recent years this unit has been involved in the development and biological characterisation of micro- and nano-delivery systems for topical application.

About Almirall

Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of programs including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers unmet needs.

Founded in 1943, headquartered in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totaled 859.3 million euros and, with more than 2,000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.

For more information, please visit www.almirall.com

Disclaimer

This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are 'forward-looking statements'. These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.

Almirall SA published this content on 18 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 18 July 2017 14:08:11 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALMIRALL SA
11/06 ALMIRALL : Q3 results 2017
11/01ALMIRALL SA : quaterly earnings release
10/27 ALMIRALL : New randomized controlled study confirms the efficacy and tolerabilit..
09/07 ALMIRALL : Phase III AMPLIFY study shows Duaklir significantly improves lung fun..
08/28 ALMIRALL : appoints Peter Guenter as new CEO
08/22 ALMIRALL : announces Ron Menezes as new President & General Manager at Aqua Phar..
07/24 ALMIRALL'S H1 RESULTS 2017 : reiterating recent Guidance
07/19ALMIRALL SA : half-yearly earnings release
07/18 ALMIRALL : collaborates with ICMAB-CSIC and Leitat Technology Center in Nanomedi..
07/10 ALMIRALL : announces Guidance Update for 2017
More news
News from SeekingAlpha
11/06 Almirall SA 2017 Q3 - Results - Earnings Call Slides
11/06 Almirall SA 2017 Q3 - Results - Earnings Call Slides
07/11 Almirall SA (LBTSF) Updates Guidance for FY17 - Slideshow
03/21 AstraZeneca's Mistakes Mount
01/13 Almirall SA (LBTSF) Presents At 35th Annual J.P. Morgan Healthcare Conference
Financials (€)
Sales 2017 693 M
EBIT 2017 52,1 M
Net income 2017 -46,6 M
Finance 2017 110 M
Yield 2017 2,07%
P/E ratio 2017 -
P/E ratio 2018 18,67
EV / Sales 2017 1,91x
EV / Sales 2018 1,70x
Capitalization 1 430 M
Chart ALMIRALL SA
Duration : Period :
Almirall SA Technical Analysis Chart | ALM | ES0157097017 | 4-Traders
Technical analysis trends ALMIRALL SA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 10,7 €
Spread / Average Target 29%
EPS Revisions
Managers
NameTitle
Peter Guenter Chief Executive Officer
Jorge Gallardo Ballart Chairman
David Nieto Chief Financial Officer
Eloi Crespo Cervera Vice President-Manufacturing & Technical Services
Bhushan D. Hardas Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALMIRALL SA-44.99%1 679
JOHNSON & JOHNSON19.78%370 552
NOVARTIS11.20%220 012
ROCHE HOLDING LTD.-1.55%212 913
PFIZER8.90%210 711
MERCK AND COMPANY-6.23%147 550